Craft

Immunovia

Stock Price

KR0.6

2024-10-29

Market Capitalization

KR109.1 M

2024-10-29

Revenue

KR685 K

FY, 2025

Immunovia Summary

Company Summary

Overview
Immunovia engages in the development of a technology platform based on antibody microarray analysis. It focuses on developing diagnosis of cancer and autoimmune diseases. The Company offers IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. It also provides IMMray Proteome Survey platform, a discovery tool for proteome scanning. 
Type
Public
Status
Active
Founded
2007
HQ
Lund, SE | view all locations
Website
https://immunovia.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Mats Grahn

    Mats Grahn, Director

    LocationsView all

    3 locations detected

    • Lund, Skåne län HQ

      Sweden

      Medicon Village Scheelevägen 2

    • Marlborough, MA

      United States

      26 Forest St #110, Marlborough

    • Lund, Skåne län

      Sweden

      Scheelevägen 2

    Immunovia Financials

    Summary Financials

    Revenue (FY, 2025)
    kr685.0K
    Gross profit (FY, 2025)
    kr549.0K
    Net income (FY, 2025)
    (kr145.9M)
    Cash (FY, 2025)
    kr77.5M
    EBIT (FY, 2025)
    (kr80.5M)
    Enterprise value
    $32.5M

    Footer menu